REGISTER FOR THE 2024 CONFERENCE
Shopping Cart

No products in the cart.

Cancer-associated_cachexia

Hepatic gluconeogenesis and PDK3 upregulation drive cancer cachexia in flies and mice.

Cachexia, a severe wasting syndrome characterized by tumour-induced metabolic dysregulation, is a leading cause of death in people with cancer, yet its underlying mechanisms remain poorly understood. Here we show that a longitudinal full-body single-nuclei-resolution transcriptome analysis in a Drosophila...
๐Ÿ—“๏ธ 2025-04-16
Read MoreHepatic gluconeogenesis and PDK3 upregulation drive cancer cachexia in flies and mice.

Myocellular adaptations to short-term weighted wheel-running exercise are largely conserved during C26-tumour induction in male and female mice.

This study investigated whether performing a translatable murine model of concurrent training after tumour induction affects adaptations in juvenile male and female tumour-bearing mice. Male and female Balb/c mice were injected bilaterally with colon-26 adenocarcinoma (C26) cells or PBS at...
๐Ÿ—“๏ธ 2025-04-24
๐Ÿ“ฐ Publication: Experimental Physiology
Read MoreMyocellular adaptations to short-term weighted wheel-running exercise are largely conserved during C26-tumour induction in male and female mice.

INFLAMMATION IN CANCER CACHEXIA: STILL THE CENTRAL TENET OR JUST ANOTHER PLAYER?

Cancer cachexia, a multifactorial syndrome characterised by body weight loss, muscle and adipose tissue wasting, affects cancer patients. Over time, the definition of cachexia has been modified, including inflammation as one of the main causal factors. Evidences have suggested that...
๐Ÿ—“๏ธ 2025-04-18
๐Ÿ“ฐ Publication: American Journal Of Physiology-Cell Physiology
Read MoreINFLAMMATION IN CANCER CACHEXIA: STILL THE CENTRAL TENET OR JUST ANOTHER PLAYER?

Blood-Brain Barrier-Penetrating Nanocarriers Enable Microglial-Specific Drug Delivery in Hypothalamic Neuroinflammation.

Hypothalamic inflammation plays a pivotal role in appetite dysregulation across various pathological conditions, including cancer cachexia. However, delivering anti-inflammatory agents to microglia, key mediators of hypothalamic inflammation, remains challenging due to the unsurmountable blood-brain barrier (BBB). To overcome this challenge,...
๐Ÿ—“๏ธ 2025-04-03
๐Ÿ“ฐ Publication: Advanced Healthcare Materials
Read MoreBlood-Brain Barrier-Penetrating Nanocarriers Enable Microglial-Specific Drug Delivery in Hypothalamic Neuroinflammation.

Nuciferine Attenuates Cancer Cachexia-Induced Muscle Wasting in Mice via HSP90AA1.

Around 80% of patients with advanced cancer have cancer cachexia (CC), a serious complication for which there are currently no FDA-approved treatments. Nuciferine (NF) is the main active ingredient of lotus leaf, which has anti-inflammatory, anti-tumour and other effects. The...
๐Ÿ—“๏ธ 2025-04-01
๐Ÿ“ฐ Publication: Journal Of Cachexia Sarcopenia And Muscle
Read MoreNuciferine Attenuates Cancer Cachexia-Induced Muscle Wasting in Mice via HSP90AA1.

A Dynamic Time Warping Extension to Consensus Weight-Based Cachexia Criteria Improves Prediction of Cancer Patient Outcomes.

Cachexia is a complex syndrome that impacts up to half of patients with cancer. Criteria systems have been developed for the purpose of diagnosing and grading cachexia severity in clinical settings. One of the most widely known is those developed...
๐Ÿ—“๏ธ 2025-01-29
Read MoreA Dynamic Time Warping Extension to Consensus Weight-Based Cachexia Criteria Improves Prediction of Cancer Patient Outcomes.

Oncological and Survival Endpoints in Cancer Cachexia Clinical Trials: Systematic Review 6 of the Cachexia Endpoints Series.

In patients receiving anti-cancer treatment, cachexia results in poorer oncological outcomes. However, there is limited understanding and no systematic review of oncological endpoints in cancer cachexia (CC) trials. This review examines oncological endpoints in CC clinical trials. An electronic literature...
๐Ÿ—“๏ธ 2025-04-01
๐Ÿ“ฐ Publication: Journal Of Cachexia Sarcopenia And Muscle
Read MoreOncological and Survival Endpoints in Cancer Cachexia Clinical Trials: Systematic Review 6 of the Cachexia Endpoints Series.

Multicomponent Interventions for Adults With Cancer Cachexia: A Systematic Review.

Cancer cachexia has substantial impacts on people's quality of life. There is no current gold standard treatment, but the complex pathophysiology of cachexia suggests that a multitargeted and individualised treatment approach is needed. We aimed to evaluate the extent to...
๐Ÿ—“๏ธ 2025-04-01
๐Ÿ“ฐ Publication: Journal Of Cachexia Sarcopenia And Muscle
Read MoreMulticomponent Interventions for Adults With Cancer Cachexia: A Systematic Review.

Corrigendum to "Identifying cancer cachexia in patients without weight loss information: machine learning approaches to address a real-world challenge" Am J Clin Nutr 116 (2022) 1229-1239.

๐Ÿ—“๏ธ 2025-02-12
๐Ÿ“ฐ Publication: American Journal Of Clinical Nutrition
Read MoreCorrigendum to "Identifying cancer cachexia in patients without weight loss information: machine learning approaches to address a real-world challenge" Am J Clin Nutr 116 (2022) 1229-1239.

Diagnostic Criteria for Cancer-Associated Cachexia: Insights from a Multicentre Cohort Study.

To explore the association between cachexia, as defined by different diagnostic criteria, and the risk of mortality in individuals with cancer. We also examined which diagnostic criteria are more feasible and appropriate for cancer-associated cachexia in clinical practice. A multicentre...
๐Ÿ—“๏ธ 2025-02-01
๐Ÿ“ฐ Publication: Journal Of Cachexia Sarcopenia And Muscle
Read MoreDiagnostic Criteria for Cancer-Associated Cachexia: Insights from a Multicentre Cohort Study.

Early identification of potentially reversible cancer cachexia using explainable machine learning driven by body weight dynamics: a multicenter cohort study.

Cachexia is associated with multiple adverse outcomes in cancer. However, clinical decision-making for oncology patients at the cachexia stage presents significant challenges. This study aims to develop a machine learning (ML) model to identify potentially reversible cancer cachexia (PRCC). This...
๐Ÿ—“๏ธ 2025-01-08
๐Ÿ“ฐ Publication: American Journal Of Clinical Nutrition
Read MoreEarly identification of potentially reversible cancer cachexia using explainable machine learning driven by body weight dynamics: a multicenter cohort study.

Selpercatinib mitigates cancer cachexia independent of anti-tumor activity in the HT1080 tumor model.

Anorexia is a major cause of cancer cachexia and is induced by growth differentiation factor-15 (GDF15), which activates the rearranged during transfection (RET) protein tyrosine kinase in the hindbrain through GDF family receptor ฮฑ-like (GFRAL), raising the possibility of targeting...
๐Ÿ—“๏ธ 2025-01-06
๐Ÿ“ฐ Publication: Cancer Letters
Read MoreSelpercatinib mitigates cancer cachexia independent of anti-tumor activity in the HT1080 tumor model.

Brown adipose tissue is associated with reduced weight loss and risk of cancer cachexia: A retrospective cohort study.

Brown adipose tissue (BAT) has been mainly investigated as a potential target against cardiometabolic disease, but it has also been linked to cancer-related outcomes. Although preclinical data support that BAT and the thermogenic adipocytes in white adipose tissue may play...
๐Ÿ—“๏ธ 2024-12-30
๐Ÿ“ฐ Publication: Clinical Nutrition
Read MoreBrown adipose tissue is associated with reduced weight loss and risk of cancer cachexia: A retrospective cohort study.

Local Inflammation Precedes Diaphragm Wasting and Fibrotic Remodelling in a Mouse Model of Pancreatic Cancer.

Cancer cachexia represents a debilitating muscle wasting condition that is highly prevalent in gastrointestinal cancers, including pancreatic ductal adenocarcinoma (PDAC). Cachexia is estimated to contribute to ~30% of cancer-related deaths, with deterioration of respiratory muscles suspected to be a key...
๐Ÿ—“๏ธ 2025-02-01
๐Ÿ“ฐ Publication: Journal Of Cachexia Sarcopenia And Muscle
Read MoreLocal Inflammation Precedes Diaphragm Wasting and Fibrotic Remodelling in a Mouse Model of Pancreatic Cancer.

Novel oral compound Z526 mitigates cancer-associated cachexia via intervening NF-ฮบB signaling and oxidative stress.

Cancer-associated cachexia (CAC) is a severe metabolic disorder syndrome mainly characterized by muscle and fat loss, which accounts for one-third of cancer-related deaths. No effective therapeutic approach that could fully reverse CAC is available. NF-ฮบB signaling and oxidative stress play...
๐Ÿ—“๏ธ 2024-04-08
๐Ÿ“ฐ Publication: Genes & Diseases
Read MoreNovel oral compound Z526 mitigates cancer-associated cachexia via intervening NF-ฮบB signaling and oxidative stress.

Subscribe to the SCWD Newsletter

Stay Informed with the Latest Updates and Exclusive Insights!